Cipla has launched its Synchrobreathe breath actuated inhaler in South Africa, the company announced. In 2015, Cipla had said that it expected to launch the inhaler by the end of that year. Cipla Medpro CEO Paul Miller said, “Incorrect use of inhalers and non-adherence to treatment are major contributors to the poor levels of asthma control we experience in South … [Read more...] about Cipla launches the Synchrobreathe inhaler in South Africa
Business
NasoShield developer Altimmune to merge with PharmAthene
Altimmune, which is developing intranasal vaccines against influenza and anthrax, is set to merge with vaccine developer PharmAthene, the companies have announced. Altimmune will become a wholly-owned subsidiary of PharmAthene subject to stockholder approval of the all-stock transaction, and the combined company will operate under the name Altimmune. After years … [Read more...] about NasoShield developer Altimmune to merge with PharmAthene
Mast Therapeutics to merge with Savara
AIR001 developer Mast Therapeutics will merge with AeroVanc and Molgradex developer Savara, the companies have announced. Savara's current management team will lead the combined company, which will be called Savara Inc and which will trade under a new stock ticker symbol. After the merger, current Savara stockholders will own ~76% of the combined company, and current … [Read more...] about Mast Therapeutics to merge with Savara
Satsuma Pharmaceuticals spins out from SNBL to develop intranasal dihydroergotamine
Satsuma Pharmaceuticals, a spin out from Shin Nippon Biomedical Laboratories (SNBL) has closed a $12 million Series A financing co-led by RA Capital Management and TPG Biotech, the company said. Proceeds will be used to fund development of the company's STS101 dihydroergotamine (DHE) intranasal dry powder for the treatment of migraines. In 2013, SNBL announced … [Read more...] about Satsuma Pharmaceuticals spins out from SNBL to develop intranasal dihydroergotamine
BAT returns Voke inhaler rights to Kind Consumer
Days after its subsidiary Nicovations cancelled supply agreements with Bespak, British American Tobacco says that it and Kind Consumer "have reached a mutually satisfactory agreement on the financial aspects" on "a new approach to commercialize the Voke nicotine inhaler" in which BAT will return the rights to the inhaler to Kind, "allowing Kind to embrace the full … [Read more...] about BAT returns Voke inhaler rights to Kind Consumer
Nicovations terminates Bespak supply agreements for Voke nicotine inhaler
Bespak parent company Consort Medical has confirmed that British American Tobacco subsidiary Nicovations has terminated its supply agreements with Bespak for the Voke nicotine inhaler, effective immediately. According to Consort, Nicovations invoked a clause in the agreement allowing it to cancel in the event that the product failed to reach commercial launch by 31 … [Read more...] about Nicovations terminates Bespak supply agreements for Voke nicotine inhaler
Vectura and Mundipharma sign development deal for triple therapy MDI
Vectura and Mundipharma have signed an agreement for the development and commercialization of the VR2076 ICS/LABA/LAMA MDI, Vectura has announced. Skyepharma, which was acquired by Vectura earlier this year, had previously announced a development and commercialization deal for the MDI, then known as SKP-2076, in December 2015. Mundipharma and a "US associated … [Read more...] about Vectura and Mundipharma sign development deal for triple therapy MDI
Horizon launches Quinsair inhaled levofloxacin in Canada
Horizon Pharma has announced that Quinsair levofloxacin inhalation solution is now available in Canada for the treatment of P. aeruginosa lung infections in adult cystic fibrosis patients. Horizon acquired Quinsair when it acquired Raptor Pharmaceutical company in October 2016. Raptor launched Quinsair in Europe in April 2016. Horizon Pharma VP and General Manager, … [Read more...] about Horizon launches Quinsair inhaled levofloxacin in Canada
Sunovion gets US rights to Utibron, Seebri, and Arcapta Neohalers
Sunovion has acquired exclusive US marketing rights to three Novartis DPIs for the treatment of COPD, the company has announced. The company said that it plans to market the Utibron (indacaterol/glycopyrrolate) Neohaler, Seebri (glycopyrrolate) Neohaler, and Arcapta (indacaterol) Neohaler beginning in 2017. Novartis will continue to manufacture the three … [Read more...] about Sunovion gets US rights to Utibron, Seebri, and Arcapta Neohalers
Capsugel to be acquired by Lonza
Lonza Group will acquire capsule manufacturer and CDMO Capsugel from KKR for $5.5 billion, the company has announced. The deal has been approved by the boards of both companies and is expected to close by mid-2017. KKR acquired Capsugel from Pfizer in 2011 for a little less than $2.4 billion. Capsugel manufactures capsules for DPIs and offers development and … [Read more...] about Capsugel to be acquired by Lonza